| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d304f6bb4e2909cfa10a856d65280d24 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-35 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605 |
| filingDate |
2008-03-27^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2ad2ebcb5a2129f360a622cfeb11d69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51cd42e4a61cad3bb91e22a1a5641d7b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb0dbe129acc93d9be2f3f04ef29dd47 |
| publicationDate |
2009-12-09^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2129687-A2 |
| titleOfInvention |
Novel glp-1 fusion peptides, their production and use |
| abstract |
The present invention provides novel fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1 (7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. Component (II) is preferably a full or partial version of a homologue of native IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1 (7-35, 36 or 37)/IP2- homologue/GLP-1(7-35, 36 or 37) or GLP-2. The fusion peptide may be produced in engineered cells or synthetically and may be used for the preparation of a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders. |
| priorityDate |
2007-03-27^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |